Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions

Philip Todd Korthuis; Joshua S. Josephs; John A. Fleishman; James Hellinger; Seth Himelhoch; Geetanjali Chander; Elizabeth B. Morse; Kelly A. Gebo

doi:10.1016/j.jsat.2007.11.005

Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions

Philip Todd Korthuis
, Joshua S. Josephs
, John A. Fleishman
, James Hellinger
, Seth Himelhoch
, Geetanjali Chander
, Elizabeth B. Morse
, Kelly A. Gebo

Producción científica: Article › revisión exhaustiva

34 Citas (Scopus)

Resumen

Substance abuse treatment is associated with decreases in human immunodeficiency virus (HIV) risk behavior and can improve HIV outcomes. The purpose of this study was to examine factors associated with substance abuse treatment utilization, including patient-provider discussions of substance use issues. We surveyed 951 HIV-infected adults receiving care at 14 HIV Research Network primary care sites regarding drug and alcohol use, substance abuse treatment, and provider discussions of substance use issues. Although 71% reported substance use, only 24% reported receiving substance abuse treatment and less than half reported discussing substance use issues with their HIV providers. In adjusted logistic regression models, receipt of substance abuse treatment was associated with patient-provider discussions. Patient-provider discussions of substance use issues were associated with current drug use, hazardous or binge drinking, and Black race or ethnicity, though substance use was comparable between Blacks and Whites. These data suggest potential opportunities for improving engagement in substance abuse treatment services.

Idioma original	English
Páginas (desde-hasta)	294-303
Número de páginas	10
Publicación	Journal of Substance Abuse Treatment
Volumen	35
N.º	3
DOI	https://doi.org/10.1016/j.jsat.2007.11.005
Estado	Published - oct 2008

Nota bibliográfica

Funding Information:
This work was supported by the Agency for Healthcare Research and Quality (AHRQ; 290-01-0012) and the National Institute on Aging (R01 AG026250), NIAAA (K23 AA015313), and National Institute on Drug Abuse (K23-DA00523, K23-DA019809, and K23-DA019820). Dr. Gebo was also supported by the Johns Hopkins University Richard Ross Clinician Scientist Award. The views expressed in this article are those of the authors. No official endorsement by the Department of Health and Human Services, the National Institutes of Health, or the AHRQ is intended or should be inferred. Special thanks to Moriah McSharry McGrath, MPH, MSUP, for assistance in manuscript preparation. Preliminary results were presented in abstract form at the International AIDS Conference (August 2006, Toronto, Canada) and the annual Society of General Internal Medicine meeting (April 2007, Toronto, Canada).

Financiación

This work was supported by the Agency for Healthcare Research and Quality (AHRQ; 290-01-0012) and the National Institute on Aging (R01 AG026250), NIAAA (K23 AA015313), and National Institute on Drug Abuse (K23-DA00523, K23-DA019809, and K23-DA019820). Dr. Gebo was also supported by the Johns Hopkins University Richard Ross Clinician Scientist Award. The views expressed in this article are those of the authors. No official endorsement by the Department of Health and Human Services, the National Institutes of Health, or the AHRQ is intended or should be inferred. Special thanks to Moriah McSharry McGrath, MPH, MSUP, for assistance in manuscript preparation. Preliminary results were presented in abstract form at the International AIDS Conference (August 2006, Toronto, Canada) and the annual Society of General Internal Medicine meeting (April 2007, Toronto, Canada).

Financiadores	Número del financiador
National Institute on Drug Abuse	K23-DA00523, K23-DA019820, K23-DA019809
National Institute on Alcohol Abuse and Alcoholism	K23 AA015313
National Institute on Aging	R01AG026250
Agency for Healthcare Research and Quality	290-01-0012
The Johns Hopkins University

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Psychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Acceder al documento

10.1016/j.jsat.2007.11.005

Otros archivos y enlaces

Citar esto

@article{312226586ff94d9091a01311827d59f7,

title = "Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions",

abstract = "Substance abuse treatment is associated with decreases in human immunodeficiency virus (HIV) risk behavior and can improve HIV outcomes. The purpose of this study was to examine factors associated with substance abuse treatment utilization, including patient-provider discussions of substance use issues. We surveyed 951 HIV-infected adults receiving care at 14 HIV Research Network primary care sites regarding drug and alcohol use, substance abuse treatment, and provider discussions of substance use issues. Although 71\% reported substance use, only 24\% reported receiving substance abuse treatment and less than half reported discussing substance use issues with their HIV providers. In adjusted logistic regression models, receipt of substance abuse treatment was associated with patient-provider discussions. Patient-provider discussions of substance use issues were associated with current drug use, hazardous or binge drinking, and Black race or ethnicity, though substance use was comparable between Blacks and Whites. These data suggest potential opportunities for improving engagement in substance abuse treatment services.",

keywords = "African Americans, Communication, HIV, Health services accessibility, Substance-related disorders, Transportation",

author = "Korthuis, \{Philip Todd\} and Josephs, \{Joshua S.\} and Fleishman, \{John A.\} and James Hellinger and Seth Himelhoch and Geetanjali Chander and Morse, \{Elizabeth B.\} and Gebo, \{Kelly A.\}",

note = "Funding Information: This work was supported by the Agency for Healthcare Research and Quality (AHRQ; 290-01-0012) and the National Institute on Aging (R01 AG026250), NIAAA (K23 AA015313), and National Institute on Drug Abuse (K23-DA00523, K23-DA019809, and K23-DA019820). Dr. Gebo was also supported by the Johns Hopkins University Richard Ross Clinician Scientist Award. The views expressed in this article are those of the authors. No official endorsement by the Department of Health and Human Services, the National Institutes of Health, or the AHRQ is intended or should be inferred. Special thanks to Moriah McSharry McGrath, MPH, MSUP, for assistance in manuscript preparation. Preliminary results were presented in abstract form at the International AIDS Conference (August 2006, Toronto, Canada) and the annual Society of General Internal Medicine meeting (April 2007, Toronto, Canada). ",

year = "2008",

month = oct,

doi = "10.1016/j.jsat.2007.11.005",

language = "English",

volume = "35",

pages = "294--303",

number = "3",

}

TY - JOUR

T1 - Substance abuse treatment in human immunodeficiency virus

T2 - The role of patient-provider discussions

AU - Korthuis, Philip Todd

AU - Josephs, Joshua S.

AU - Fleishman, John A.

AU - Hellinger, James

AU - Himelhoch, Seth

AU - Chander, Geetanjali

AU - Morse, Elizabeth B.

AU - Gebo, Kelly A.

N1 - Funding Information: This work was supported by the Agency for Healthcare Research and Quality (AHRQ; 290-01-0012) and the National Institute on Aging (R01 AG026250), NIAAA (K23 AA015313), and National Institute on Drug Abuse (K23-DA00523, K23-DA019809, and K23-DA019820). Dr. Gebo was also supported by the Johns Hopkins University Richard Ross Clinician Scientist Award. The views expressed in this article are those of the authors. No official endorsement by the Department of Health and Human Services, the National Institutes of Health, or the AHRQ is intended or should be inferred. Special thanks to Moriah McSharry McGrath, MPH, MSUP, for assistance in manuscript preparation. Preliminary results were presented in abstract form at the International AIDS Conference (August 2006, Toronto, Canada) and the annual Society of General Internal Medicine meeting (April 2007, Toronto, Canada).

PY - 2008/10

Y1 - 2008/10

N2 - Substance abuse treatment is associated with decreases in human immunodeficiency virus (HIV) risk behavior and can improve HIV outcomes. The purpose of this study was to examine factors associated with substance abuse treatment utilization, including patient-provider discussions of substance use issues. We surveyed 951 HIV-infected adults receiving care at 14 HIV Research Network primary care sites regarding drug and alcohol use, substance abuse treatment, and provider discussions of substance use issues. Although 71% reported substance use, only 24% reported receiving substance abuse treatment and less than half reported discussing substance use issues with their HIV providers. In adjusted logistic regression models, receipt of substance abuse treatment was associated with patient-provider discussions. Patient-provider discussions of substance use issues were associated with current drug use, hazardous or binge drinking, and Black race or ethnicity, though substance use was comparable between Blacks and Whites. These data suggest potential opportunities for improving engagement in substance abuse treatment services.

AB - Substance abuse treatment is associated with decreases in human immunodeficiency virus (HIV) risk behavior and can improve HIV outcomes. The purpose of this study was to examine factors associated with substance abuse treatment utilization, including patient-provider discussions of substance use issues. We surveyed 951 HIV-infected adults receiving care at 14 HIV Research Network primary care sites regarding drug and alcohol use, substance abuse treatment, and provider discussions of substance use issues. Although 71% reported substance use, only 24% reported receiving substance abuse treatment and less than half reported discussing substance use issues with their HIV providers. In adjusted logistic regression models, receipt of substance abuse treatment was associated with patient-provider discussions. Patient-provider discussions of substance use issues were associated with current drug use, hazardous or binge drinking, and Black race or ethnicity, though substance use was comparable between Blacks and Whites. These data suggest potential opportunities for improving engagement in substance abuse treatment services.

KW - African Americans

KW - Communication

KW - HIV

KW - Health services accessibility

KW - Substance-related disorders

KW - Transportation

UR - https://www.scopus.com/pages/publications/51449098858

UR - https://www.scopus.com/pages/publications/51449098858#tab=citedBy

U2 - 10.1016/j.jsat.2007.11.005

DO - 10.1016/j.jsat.2007.11.005

M3 - Article

C2 - 18329222

AN - SCOPUS:51449098858

SN - 0740-5472

VL - 35

SP - 294

EP - 303

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

IS - 3

ER -

Substance abuse treatment in human immunodeficiency virus: The role of patient-provider discussions

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto